Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Jan 15, 2007 (Vol. 27, No. 2)


  • Outstanding coverage
  • Nothing significant
My evaluation of this one had its ups and downs. The title caught my eye. A quick read of the About Biosingularity, however, left me with a sinking feeling that the author was a bit over the top with the word. A step back to the main page, however, revealed a great selection of articles on health, biology, aging, and other topics related to living organisms. I’d find it hard to believe any biologist would not find things of interest here. The topics are wonderful and make fascinating reading. When I viewed this site, they included the protective effects of alpha lipoic acid against atherosclerosis, the transformation of immune cells into tumor fighters, the little known antibiotic that appears to have promise as an anticancer agent, and much more. Indeed, the articles I note appeared on the page in the span of 13 days. I don’t know of a better site out there that covers its topic so concisely. My hat goes off to the designer even if I’m not fond of the concept of biosingularity.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good

*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »